Skip to main content
HairCited

Finasteride pour Alopécie Androgénétique

A

Basé sur 129 études (16 meta-analyses, 13 RCTs) avec 18,623 participants au total. 106/129 études montrent des effets positifs.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dfinasteride\u0026condition\u003Dandrogenetic\u002Dalopecia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

En conclusion

Finasteride has very strong evidence supporting its effectiveness for androgenetic alopecia and is considered a well-established first-line option backed by decades of research.

  • 106 out of 129 studies show positive effects — one of the most studied hair loss interventions
  • 16 meta-analyses and 13 RCTs provide a robust evidence base across 18,623 participants
  • Works by reducing DHT, the hormone primarily responsible for pattern hair loss
  • Topical finasteride formulations are being researched as an alternative to oral use

Key Study Findings

Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs: None Outcome: None Effet: None None

Population: women with androgenetic alopecia (female pattern hair loss)

non-randomized controlled trial n=60 16 weeks Open-label
Clinical Efficacy and Mechanisms of Microneedling Alone or Combined With Drugs in the Treatment of …
Dose: Mild group: microneedling alone (8 weeks); Moderate group: microneedling + 5% minoxidil (12 weeks); vs: Placebo Effet: All groups showed significant decrease in HLSS and increase in hair density post-treatment (p<0.001) p<0.001
randomized controlled trial n=45 16 weeks Open-label
Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in …
Dose: Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi vs: Placebo Effet: Groups A and C showed significant improvement on Sinclair scale and trichoscopic hair density; Group None
Review
Male and female pattern hair loss.
Dose: None vs: Placebo Effet: None None
randomized controlled trial n=45 Open-label
Clinical efficacy of microneedle combined with 5% Minoxidil solution and finasteride in the treatment of …
Dose: Group A: 5% Minoxidil alone; Group B: 5% Minoxidil + Finasteride; Group C: Microneedling + 5% Minoxi vs: Placebo Effet: Hair density and hair shaft diameter increased in all groups; Group C superior to Group A in Norwood p<0.01

Key Statistics

206

Études

24777

Participants

Positive

A

Note

Referenced Papers

Aesthetic plastic surgery 2025 14 citations
Anais brasileiros de … 2025 7 citations
International journal of … 2025 5 citations
Journal of cosmetic … 2025 3 citations
European journal of … 2025 3 citations
Australian prescriber 2025 2 citations
Skin appendage disorders 2025 1 citations
Nature reviews. Disease … 2025
Annals of dermatology 2025
International journal of … 2024 39 citations
Indian journal of … 2024 14 citations
Dermatology (Basel, Switzerland) 2024 14 citations
Journal of cosmetic … 2024 11 citations
Journal of clinical … 2024 10 citations
Facial plastic surgery … 2024 8 citations
American family physician 2024 8 citations
Photodermatology, photoimmunology & … 2024 8 citations
International journal of … 2024 5 citations
Drugs 2023 221 citations
JAAD international 2023 80 citations
Clinical, cosmetic and … 2023 58 citations
American journal of … 2023 41 citations
Anais brasileiros de … 2023 29 citations
Dermatology and therapy 2023 23 citations
International journal of … 2023 5 citations
Journal der Deutschen … 2023 5 citations
Journal of cosmetic … 2023 3 citations
BMJ case reports 2023 2 citations
Clinics in plastic … 2023 1 citations
International journal of … 2023 1 citations
The Journal of … 2022 65 citations
Faculty reviews 2022 44 citations
Dermatologic therapy 2022 41 citations
Archivos espanoles de … 2022 9 citations
Cureus 2022 3 citations
Facial plastic surgery … 2022
Journal of cutaneous … 2021 44 citations
Journal of the … 2021 42 citations
Expert opinion on … 2020 147 citations
Fertility and sterility 2020 94 citations
Neurobiology of stress 2020 72 citations
Facial plastic surgery … 2020 15 citations
Dermatologic clinics 2020 15 citations
Alternative therapies in … 2020 11 citations
Journal of cosmetic … 2019 100 citations
Assay and drug … 2019 19 citations
The aging male … 2019 19 citations
International journal of … 2018 129 citations
Indian journal of … 2018 79 citations
Lasers in medical … 2018 75 citations
Expert opinion on … 2018 38 citations
Endocrine 2017 442 citations
JAMA dermatology 2017 121 citations
Current clinical pharmacology 2017 62 citations
Actas dermo-sifiliograficas 2017 17 citations
Deutsches Arzteblatt international 2016 99 citations
The Cochrane database … 2016 18 citations
Indian journal of … 2016 8 citations
The Medical clinics … 2015 66 citations
Current problems in … 2015 8 citations
Der Internist 2015
Lasers in surgery … 2014 243 citations
Journal of cutaneous … 2014 168 citations
Expert opinion on … 2014 57 citations
Current opinion in … 2014 43 citations
Journal of drugs … 2014 26 citations
Giornale italiano di … 2014 8 citations
Indian journal of … 2013 196 citations
Dermatologic clinics 2013 78 citations
Journal of cosmetic … 2013 62 citations
Facial plastic surgery … 2013 16 citations
International journal of … 2013
Expert opinion on … 2010 264 citations
Current opinion in … 2009 54 citations
Seminars in cutaneous … 2009 4 citations
American family physician 2009
Nihon rinsho. Japanese … 2008 6 citations
Endocrinology and metabolism … 2007 33 citations
Acta dermatovenerologica Alpina, … 2005
Revue medicale de … 2004
Praxis 2003 28 citations
American family physician 2003
Molecular and cellular … 2002
American journal of … 2000 18 citations
Southern medical journal 2000
International journal of … 1999
American family physician 1999
Journal of the … 1999
Current pharmaceutical design 1999
Journal of cutaneous … 1999
Dermatologic clinics 1998 121 citations
Annales de dermatologie … 1997

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Posologies couramment utilisées

hairloss:
1 mg/day oral

Limite supérieure : 5 mg/day (BPH dose)

Posologies étudiées dans la recherche

Posologie Durée Effet N
None -- Neutral --
None -- Neutral --
Mild group: microneedling alone (8 weeks); Moderate group: microneedling + 5% minoxidil (12 weeks); 16 weeks Positive 60
Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi 16 weeks Positive 45
None -- Positive --
Group A: 5% Minoxidil alone; Group B: 5% Minoxidil + Finasteride; Group C: Microneedling + 5% Minoxi -- Positive 45
None -- Positive --
various across included studies (2015-2024) -- Positive --

Moment optimal de prise : Once daily at the same time, with or without food

Safety & Side Effects

Effets indésirables signalés

  • Decreased libido (2-4% of users)
  • Erectile dysfunction (1-3% of users)
  • Decreased ejaculate volume
  • Breast tenderness or gynecomastia (rare)
  • Depression or mood changes (rare, debated)

Interactions connues

  • No significant drug-drug interactions identified
  • May affect PSA test results (reduces PSA by ~50%)
  • Contraindicated in pregnancy (Category X teratogen)

Apport maximal tolérable : 5 mg/day (BPH dose)

Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.

Frequently Asked Questions

Does Finasteride help with Alopécie Androgénétique?
Based on 206 studies with 24,777 participants, there is strong evidence from multiple clinical trials that Finasteride may support Alopécie Androgénétique management. Our evidence grade is A (Strong Evidence).
How much Finasteride should I take for Alopécie Androgénétique?
Studies have used various dosages. A commonly studied range is 1 mg/day oral. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Finasteride?
Reported side effects may include Decreased libido (2-4% of users), Erectile dysfunction (1-3% of users), Decreased ejaculate volume, Breast tenderness or gynecomastia (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Finasteride and Alopécie Androgénétique?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 206 peer-reviewed studies with 24,777 total participants. The overall direction of effect is positive.

Related Evidence

Avertissement FDA: Ces déclarations n'ont pas été évaluées par la Food and Drug Administration. Les produits et informations sur ce site ne sont pas destinés à diagnostiquer, traiter, guérir ou prévenir quelque maladie que ce soit. Les notes de preuve présentées sont basées sur notre analyse de la recherche publiée et évaluée par des pairs et ne constituent pas un avis médical. Consultez toujours votre professionnel de santé avant de commencer tout régime de compléments alimentaires.